Idorsia Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IDORSIA, and when can generic versions of IDORSIA drugs launch?
IDORSIA has two approved drugs.
There are eight US patents protecting IDORSIA drugs.
There are one hundred and forty-eight patent family members on IDORSIA drugs in thirty-six countries and twelve supplementary protection certificates in eleven countries.
Summary for Idorsia
| International Patents: | 148 |
| US Patents: | 8 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Idorsia
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 10,919,881 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 8,324,232 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 11,174,247 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | 9,732,075 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 10,023,560 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Idorsia Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101689093 | ⤷ Subscribe |
| Portugal | 2855453 | ⤷ Subscribe |
| South Korea | 20180115804 | ⤷ Subscribe |
| Mexico | 2014014885 | ⤷ Subscribe |
| Hong Kong | 1144196 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2018154101 | ⤷ Subscribe |
| South Korea | 102568472 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Idorsia Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2855453 | 122022000059 | Germany | ⤷ Subscribe | PRODUCT NAME: DARIDOREXANT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE DARIDOREXANT-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1638 20220429 |
| 2855453 | LUC00279 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: DARIDOREXANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU 1/22/1638 20220502 |
| 2855453 | PA2022518 | Lithuania | ⤷ Subscribe | PRODUCT NAME: DARIDOREKSANTAS; REGISTRATION NO/DATE: 1/22/1638/001-006 20220429 |
| 2855453 | 36/2022 | Austria | ⤷ Subscribe | PRODUCT NAME: DARIDOREXANT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE DARIDOREXANTHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1638 (MITTEILUNG) 20220502 |
| 2855453 | C202230046 | Spain | ⤷ Subscribe | PRODUCT NAME: DARIDOREXANT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR DARIDOREXANT HIDROCLORURO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1638; DATE OF AUTHORISATION: 20220429; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1638; DATE OF FIRST AUTHORISATION IN EEA: 20220429 |
| 2855453 | 2290037-7 | Sweden | ⤷ Subscribe | PRODUCT NAME: DARIDOREXANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR DARIDOREXANT HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1638/001-006 20220502 |
| 2855453 | 2022C/543 | Belgium | ⤷ Subscribe | PRODUCT NAME: DARIDOREXANT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU/1/22/1638 20220502 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
